Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise

FDA Warns of Serious Botox Side Effects

May 1, 2008 by Mobility Management

The Food & Drug Administration (FDA) has announced that Botox, Botox Cosmetic and Myobloc have been linked to serious adverse reactions when used in a variety of dosages to treat a number of different conditions.In its public statement, the FDA listed respiratory failure and death among the reported side effects, but also said those reactions “may be related to overdosing.”

Botox and Myobloc are types of botulism toxins, and Botox Cosmetic is best known for temporarily improving the appearances of wrinkles such as “frown lines.” But Botox and Myobloc have also been approved to treat certain types of muscle spasms and muscle contractions.

“FDA is aware of the body of literature describing the use of botulinum toxins to treat limb spasticity in children and adults,” the news release said. “The safety, efficacy and dosage of botulinum toxins have not been established for the treatment of limb spasticity of cerebral palsy or for use in any condition in children less than 12 years of age.”

The serious side effects seem to result, the FDA reported, when the toxins spread beyond their original injection sites: “The most serious cases had outcomes that included hospitalization and death, and occurred mostly in children treated for cerebral palsy-associated limb spasticity.” The FDA said such use is not approved in the United States. Side effects have been noted as soon as the day after an injection and up to several weeks post-injection, the FDA said.

Related Articles Read More >

New NIH, CMS Partnership Aims to Build ‘Data Platform’ for Research on Chronic Conditions
Despite assurances that patient privacy will be protected, some health-care stakeholders are wary about data sharing.
MaRS, Toyota Mobility Foundation Call for Startups to Join Mobility Unlimited Hub in Toronto
The program provides funding, technical and marketing support to cohort members.
Reviewing RESNA’s Evacuation Standard: Performance Requirements, Installations, Inspections … and Why They Matter
The standard is open for comment till June 23.
Briefly: ‘Stronger Together’ Podcast Launches May 13; Parkinson’s Researchers Seeking Volunteers for Scratch-and-Sniff Test
Featuring United Spinal Association, M.A.R.C. Network, and the Michael J. Fox Foundation.

GET THE FREE NEWSLETTER

Mobility Management Newsletter

Subscribe to Mobility Management's newsletter for industry & product news, trends and resources. Click here.
podcasts
Mobility Management
  • HME Business
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • Contact Us
  • About Us

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise